We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+58.2%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$160M
AUM Growth
+$53.9M
Cap. Flow
+$1.45M
Cap. Flow %
0.91%
Top 10 Hldgs %
86.01%
Holding
55
New
3
Increased
9
Reduced
6
Closed
1

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$996K
2
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$437K
3
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$364K
4
AMRN
Amarin Corp
AMRN
+$343K
5
MYGN icon
Myriad Genetics
MYGN
+$304K

Top Sells

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$737K
2
ATRA icon
Atara Biotherapeutics
ATRA
+$372K
3
VCYT icon
Veracyte
VCYT
+$267K
4
SITO
SITO MOBILE, LTD
SITO
+$168K
5
AMAG
AMAG Pharmaceuticals
AMAG
+$152K

Sector Composition

Rank Sector Weight
1 Healthcare 96.8%
2 Energy 2.17%
3 Consumer Staples 0.09%
4 Materials 0.08%
5 Industrials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELG
1
DELISTED
Celgene Corp
CELG
$65.9M 41.32%
699,011
– –
AXDX
2
DELISTED
Accelerate Diagnostics
AXDX
$45.9M 28.76%
218,380
– –
CMTA
3
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$5.79M 3.63%
222,000
– –
NBIX icon
4
Neurocrine Biosciences
NBIX
$17.2B
$4.85M 3.04%
55,000
– –
ARRY
5
DELISTED
Array Biopharma Inc
ARRY
$4.1M 2.57%
168,000
– –
QDEL icon
6
QuidelOrtho
QDEL
$1.19B
$3.08M 1.93%
47,075
– –
VRML
7
DELISTED
Vermillion, Inc.
VRML
$2.44M 1.53%
2,121,933
+8,000
+0.4% +$6.72K
EQM
8
DELISTED
EQM Midstream Partners, LP
EQM
$2.31M 1.45%
50,000
– –
VNDA icon
9
Vanda Pharmaceuticals
VNDA
$327M
$1.47M 0.92%
80,000
– –
OXFD
10
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$1.38M 0.87%
80,303
– –
AMRN
11
Amarin Corp
AMRN
$292M
$1.23M 0.77%
2,950
+950
+48% +$343K
ALBO
12
DELISTED
Albireo Pharma Inc
ALBO
$1.22M 0.77%
38,000
– –
MASI
13
DELISTED
Masimo
MASI
$1.11M 0.69%
8,000
– –
ARNA
14
DELISTED
Arena Pharmaceuticals Inc
ARNA
$986K 0.62%
22,000
– –
ATRA icon
15
Atara Biotherapeutics
ATRA
$75.6M
$954K 0.6%
960
-400
-29% -$372K
BMY icon
16
Bristol-Myers Squibb
BMY
$124B
$954K 0.6%
+20,000
New +$996K
WMGI
17
DELISTED
Wright Medical Group Inc
WMGI
$944K 0.59%
30,000
– –
ICPT
18
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$928K 0.58%
8,300
+4,000
+93% +$437K
HROW icon
19
Harrow
HROW
$1.74B
$896K 0.56%
180,000
– –
VCYT icon
20
Veracyte
VCYT
$4.72B
$870K 0.55%
34,767
-14,000
-29% -$267K
XLRN
21
DELISTED
Acceleron Pharma
XLRN
$870K 0.55%
18,672
– –
MYGN icon
22
Myriad Genetics
MYGN
$584M
$664K 0.42%
20,000
+10,000
+100% +$304K
DRNA
23
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$659K 0.41%
45,000
– –
IFRX icon
24
InflaRx
IFRX
$272M
$605K 0.38%
16,000
– –
BIIB icon
25
Biogen
BIIB
$30.4B
$591K 0.37%
2,500
– –
1
2 3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q1 2019 Portfolio in Review

As of Q1 2019, Birchview Capital held 55 positions worth $160M, up 51% from $106M the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Birchview Capital's Q1 2019 filing shows 3 new, 9 increased, 6 reduced and 1 closed positions. Its largest new stake was Bristol-Myers Squibb: 20,000 shares worth $954K. The largest sale was Soleno Therapeutics, an estimated $737K.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Energy and Consumer Staples.

  • Birchview Capital's largest Q1 2019 buy was Bristol-Myers Squibb: 20,000 shares worth $954K.
  • Birchview Capital added most to Intercept Pharmaceuticals, Inc. in Q1 2019, an estimated $437K increase.
  • Birchview Capital's biggest Q1 2019 reduction was Soleno Therapeutics, cutting an estimated $737K.
  • Birchview Capital fully exited AMAG Pharmaceuticals in Q1 2019, selling an estimated $152K.
  • Birchview Capital's ten largest holdings make up 86% of its $160M portfolio in Q1 2019.
  • Birchview Capital opened 3 new positions and closed 1 in Q1 2019.
  • Birchview Capital's portfolio value rose 51% quarter-over-quarter to $160M.

Based on Birchview Capital's 13F filing for Q1 2019, filed 3 May 2019.